Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. - Wikidata - awgldk - TriplyDB

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.

http://www.wikidata.org/entity/Q39835614

about

GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective Advances in the epidemiology of heart failure and left ventricular remodeling Clinical adoption of prognostic biomarkers: the case for heart failure Cardiac biomarkers: new tools for heart failure management Growth differentiation factor-15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis Systems Medicine as an Emerging Tool for Cardiovascular Genetics GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood.Change in growth differentiation factor 15, but not C-reactive protein, independently predicts major cardiac events in patients with non-ST elevation acute coronary syndrome.Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome.Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome Clinical and genetic correlates of growth differentiation factor 15 in the community Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells.Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice.Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma Inflammation and cardiac outcome Growth-differentiation factor-15 and functional outcome after acute ischemic stroke.GDF 15--A Novel Biomarker in the Offing for Heart Failure.Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study.Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening.Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study.Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation.Variability of biomarkers in patients with chronic heart failure and healthy controls.Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.Growth/differentiation factor-15: prostate cancer suppressor or promoter?Novel biomarkers in chronic heart failure.Growth differentiation factor 15 in heart failure: an update.Experimental biomarkers in heart failure: an update.Clinical use of novel biomarkers in heart failure: towards personalized medicine.Therapeutic implications of biomarkers in chronic heart failure.Circulating biomarkers in patients with heart failure and preserved ejection fraction.Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond.Biomarkers for risk prediction in acute decompensated heart failure.Biomarkers in mechanical circulatory support.Current applications of biomarkers in cardiomyopathies.The Current and Potential Clinical Relevance of Heart Failure Biomarkers.Candidate biomarkers in heart failure with reduced and preserved ejection fraction.

P2860

Q26798142-F9EB0492-7F42-46F5-807D-6A9C17623A68 Q26827147-29394CB4-ECA2-4D65-8FBC-E8E5217ED325 Q26863716-955E83F1-9A1A-4F1B-AD55-3191E55E5527 Q26991726-BE8639C1-5948-42DA-A800-A40B29097427 Q28066559-9B90F928-093D-492C-B174-8BD7FB921ECC Q28069197-7948AAF3-E2B4-40DB-8548-16A1782CBF14 Q28535575-53348EB6-D557-497E-8A7C-D6984E6FEA79 Q30371420-87CE7AD9-BFAF-4A65-917E-0BBDAAA88573 Q33563146-40725826-6869-4314-816C-F3A0D8654829 Q33754583-721444EA-222F-40EA-B158-6069CA37C365 Q34032238-2338F73B-4D3F-46FB-BDF9-A8F7B799504E Q34114806-F5BE6C1D-3C47-483A-A954-5CCF06864D5E Q34300880-85A42996-5CB6-4B83-9B8B-9ABED03020DE Q34340697-D9531236-B95A-428D-9991-50C5038AF6A9 Q35078142-0DBD8B22-7622-4B2D-86B0-F3CA4C1206D5 Q35135731-6C12CBDC-EF88-41AB-9163-909F6C500737 Q35634311-41C2B451-011E-4F60-A0B7-86C4F7BBCA41 Q35835539-2154A400-6EB1-4149-B2C8-BBC2A4D0537A Q36133676-F44C5BEF-CE08-493B-8407-6FABC7CE590C Q36728674-CC0E18F7-53ED-4298-91F5-9FBDF3D6628C Q36851584-A81E6382-2823-4A20-916E-C5614EA9FFE2 Q37153197-DF58A548-40E7-4B46-95AC-47A4E66D1C8A Q37457712-F0377759-7730-40B8-805C-888A7C359AD5 Q37588805-9A70A152-2B5B-470C-88BA-011FA820012A Q37683299-4A799BFB-C30C-423A-92D0-78154E0BD951 Q37696493-2401CF29-4C66-47A1-B987-D40ED1CB8781 Q37970489-8FB19E61-D12E-4D1F-8079-CCF6CB4D8C1C Q37988746-5C60314E-C9EE-408A-9893-3C3A4EF6CE00 Q37997237-7B0F572F-A2FD-4A52-8CF0-BB648C1D8F4E Q38041973-6939E180-1ED5-437B-A061-CE29C67E8B7F Q38055505-193E22EB-A498-405D-B90D-9DE7F9F2BE7E Q38109588-36A3DE3F-A85B-4ED7-BECD-59438CB9E965 Q38121720-53194D32-4BA1-47AB-B925-6F14DBA0C86A Q38152289-72950E5E-896C-452F-BA35-CC2BE3EAB743 Q38173317-48B090D6-7644-4478-A980-40CC3105BD89 Q38222370-5DB20D38-EC4D-4F78-B401-A731516349B6 Q38249997-40181BB4-E5E5-4CFC-877B-46DD18B40191 Q38536678-387D6AB2-7260-4924-BEDA-9C1725680C86 Q38568205-29EFD83D-DCD0-4122-8D08-E0A0C26F7BAA Q38572500-E56DEEF4-663D-48B1-BDCC-CF7307461744

P2860

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.

http://www.wikidata.org/entity/Q39835614

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Serial measurement of growth-d ...... Valsartan Heart Failure Trial.

@en

Serial measurement of growth-d ...... Valsartan Heart Failure Trial.

@nl

type

label

Serial measurement of growth-d ...... Valsartan Heart Failure Trial.

@en

Serial measurement of growth-d ...... Valsartan Heart Failure Trial.

@nl

prefLabel

Serial measurement of growth-d ...... Valsartan Heart Failure Trial.

@en

Serial measurement of growth-d ...... Valsartan Heart Failure Trial.

@nl

P1433

Q39835614-55701F64-B21A-4BB3-9B4B-1894E9FA1FA7

P1476

Q39835614-F2D2B963-B2EA-480F-AE06-F465846D5955

P2093

Q39835614-072377AB-ADB3-4F54-AB0A-E1B047159062

Q39835614-0BA6347D-CE13-4975-B938-284C33A1CD1D

Q39835614-0CFF2EC1-6845-47AA-8742-7D35434C4D17

Q39835614-4C1DFE7A-C4DF-4BA1-B3B3-3AF98C768DAA

Q39835614-4C8A8FBF-48E2-42A4-95A3-000C251901F1

Q39835614-646AA35A-0D3A-498A-A117-2DD1ECF07427

Q39835614-DB6E6FC7-A03D-4D63-B46F-E87E26B59092

Q39835614-EA393346-5324-4604-9CF3-8D0EBCF8B752

Q39835614-F916D76D-415D-4358-9B78-9C157721B976

P304

Q39835614-F227B8BC-F3E3-417D-942F-CD6979FF03B5

P31

Q39835614-957391ED-BE9F-4EA1-862B-45725E6B7ECA

P356

Q39835614-55B93730-114E-42A2-A44C-AC1CF11CD3E8

P407

Q39835614-36537BD8-CA4F-43AE-822C-0B67D8D09C99

P433

Q39835614-05FC9684-085D-46FD-A45A-BE8953469C53

P478

Q39835614-C0C8886B-BC13-4B78-A440-839741D4653C

P50

Q39835614-38A4CB55-5187-4C9A-B358-D237F2110825

P577

Q39835614-B739B235-5958-4AC9-B562-EE0EB2DAA846

P698

Q39835614-94522F0D-E412-42B3-BE9F-7D0F69B3759E

P921

Q39835614-65EE8A0E-7142-466D-B276-491D8325B316

P356

CIRCULATIONAHA.109.928846

P1433

P1476

Serial measurement of growth-d ...... Valsartan Heart Failure Trial

@en

P2093

Franziska Jantzen

http://www.w3.org/2001/XMLSchema#string

Heike Tapken

http://www.w3.org/2001/XMLSchema#string

Helmut Drexler

http://www.w3.org/2001/XMLSchema#string

Jay N Cohn

http://www.w3.org/2001/XMLSchema#string

Kai C Wollert

http://www.w3.org/2001/XMLSchema#string

Michael Kuskowski

http://www.w3.org/2001/XMLSchema#string

Thomas S Rector

http://www.w3.org/2001/XMLSchema#string

Tibor Kempf

http://www.w3.org/2001/XMLSchema#string

Tim Allhoff

http://www.w3.org/2001/XMLSchema#string

P304

1387-1395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.109.928846

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20855664

http://www.w3.org/2001/XMLSchema#string

P921